Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats

Bone

Volumn 84, Issue , 2016, Pages 148-159

  Taylor, Scott ^a   Ominsky, Michael S ^a   Hu, Rong ^a   Pacheco, Efrain ^a   He, Yudong D ^a   Brown, Danielle L ^b   Aguirre, J Ignacio ^c   Wronski, Thomas J ^c   Buntich, Sabina ^a   Afshari, Cynthia A ^a   Pyrah, Ian ^a   Nioi, Paul ^a   Boyce, Rogely Waite ^a  

^a AMGEN INC   (United States)

^b WIL RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Anabolics; Bone; Cell signaling; Osteoporosis; Therapeutics; Transcription factor; Wnt signaling

Indexed keywords

ANTIBODY; MESSENGER RNA; MYC PROTEIN; PROTEIN P53; SCLEROSTIN ANTIBODY; UNCLASSIFIED DRUG; WNT PROTEIN; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; SOST PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; BONE MASS; CELL CYCLE ARREST; CELL LINEAGE; CELL MATURATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; IMMUNOTHERAPY; LASER CAPTURE MICRODISSECTION; LONG TERM CARE; MICROARRAY ANALYSIS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOCYTE; OSTEOLYSIS; OSTEOPROGENITOR CELL; OVARIECTOMY; RAT; TIME; TWIST1 GENE; WISP1 GENE; WNT SIGNALING PATHWAY; ANIMAL; BIOLOGICAL MODEL; BONE DEVELOPMENT; CELL COUNT; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETICS; IMMUNOLOGY; METABOLISM; ORGAN SIZE; PHENOTYPE; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; STEM CELL; TIME FACTOR;

ANIMALS; ANTIBODIES; BONE MORPHOGENETIC PROTEINS; CELL COUNT; CELL LINEAGE; FEMALE; GENE EXPRESSION REGULATION; GENETIC MARKERS; MODELS, BIOLOGICAL; ORGAN SIZE; OSTEOBLASTS; OSTEOCYTES; OSTEOGENESIS; OVARIECTOMY; PHENOTYPE; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; STEM CELLS; TIME FACTORS; TRANSCRIPTION, GENETIC;

EID: 84953775790     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2015.12.013     Document Type: Article

References (57)

1. Poole K.E., van Bezooijen R.L., Loveridge N., Hamersma H., Papapoulos S.E., Löwik C.W., Reeve J. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005, 19:1842-1844.
2. Wijenayaka A.R., Kogawa M., Lim H.P., Bonewald L.F., Findlay D.M., Atkins G.J. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One 2011, 6.
3. Winkler D.G., Sutherland M.K., Geoghegan J.C., Yu C., Hayes T., Skonier J.E., Shpektor D., Jonas M., Kovacevich B.R., Staehling-Hampton K., Appleby M., Brunkow M.E., Latham J.A. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003, 22:6267-6276.
4. Ke H.Z., Richards W.G., Li X., Ominsky M.S. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 2012, 33:747-783.
5. Padhi D., Jang G., Stouch B., Fang L., Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011, 26:19-26.
6. Nioi P., Taylor S., Hu R., Pacheco E., He Y.D., Hamadeh H., Paszty C., Pyrah I., Ominsky M.S., Boyce R.W. Transcriptional profiling of laser capture microdissected subpopulations of the osteoblast lineage provides insight into the early response to sclerostin antibody in rats. J Bone Miner Res 2015, 30:1457-1467.
7. Li X., Niu Q.T., Warmington K.S., Asuncion F.J., Dwyer D., Grisanti M., Han C.Y., Stolina M., Eschenberg M.J., Kostenuik P.J., Simonet W.S., Ominsky M.S., Ke H.Z. Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26weeks of treatment with a sclerostin antibody. Endocrinology 2014, 155:4785-4797.
8. Ominsky M.S., Brown D.L., Van G., Cordover D., Pacheco E., Frazier E., Cherepow L., Higgins-Garn M., Aguirre J.I., Wronski T.J., Stolina M., Zhou L., Pyrah I., Boyce R.W. Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats. Bone 2015, 81:380-391.
9. Stolina M., Dwyer D., Niu Q.T., Villasenor K.S., Kurimoto P., Grisanti M., Han C.Y., Liu M., Li X., Ominsky M.S., Ke H.Z., Kostenuik P.J. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats. Bone 2014, 67:305-313.
10. McClung M.R., Grauer A., Boonen S., Bolognese M.A., Brown J.P., Diez-Perez A., Langdahl B.L., Reginster J.Y., Zanchetta J.R., Wasserman S.M., Katz L., Maddox J., Yang Y.C., Libanati C., Bone H.G. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014, 370:412-420.
11. National Research Council (US) Committee for the Update of the Guide of the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals 2011, National Academies Press (US), Washington, DC. eighth ed.
12. Wronski T.J., Yen C.F., Burton K.W., Mehta R.C., Newman P.S., Soltis E.E., DeLuca P.P. Skeletal effects of calcitonin in ovariectomized rats. Endocrinology 1991, 129:2246-2250.
13. Gundersen H.J. Stereology of arbitrary particles. A review of unbiased number and size estimators and the presentation of some new ones, in memory of William R. Thompson. J Microsc 1986, 143:3-45.
14. Sterio D.C. The unbiased estimation of number and sizes of arbitrary particles using the disector. J Microsc 1984, 134:127-136.
15. Langfelder P., Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 2008, 9:559.
16. Krämer A., Green J., Pollard J., Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics 2014, 30:523-530.
17. R. Nusse. The Wnt homepage: Wnt target genes. (Accessed August 25 2014). http://web.stanford.edu/group/nusselab/cgi-bin/wnt/target_genes.
18. Maeda A., Ono M., Holmbeck K., Li L., Kilts T.M., Kram V., Noonan M.L., Yoshioka Y., McNerny E.M., Tantillo M.A., Kohn D.H., Lyons K.M., Robey P.G., Young M.F. WNT1 induced secreted protein-1 (WISP1), a novel regulator of bone turnover and Wnt signaling. J Biol Chem 2015, 290:14004-14018.
19. Bellido T. Osteocyte-driven bone remodeling. Calcif Tissue Int 2014, 94:25-34.
20. Håkelien A.M., Bryne J.C., Harstad K.G., Lorenz S., Paulsen J., Sun J., Mikkelsen T.S., Myklebost O., Meza-Zepeda L.A. The regulatory landscape of osteogenic differentiation. Stem Cells 2014, 32:2780-2793.
21. Liu S., Mirza A., Wang L. Generation of p53 target database via integration of microarray and global p53 DNA-binding site analysis. Methods Mol Biol 2004, 281:33-54.
22. Spurgers K.B., Gold D.L., Coombes K.R., Bohnenstiehl N.L., Mullins B., Meyn R.E., Logothetis C.J., McDonnell T.J. Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. J Biol Chem 2006, 281:25134-25142.
23. Wei C.L., Wu Q., Vega V.B., Chiu K.P., Ng P., Zhang T., Shahab A., Yong H.C., Fu Y., Weng Z., Liu J., Zhao X.D., Chew J.L., Lee Y.L., Kuznetsov V.A., Sung W.K., Miller L.D., Lim B., Liu E.T., Yu Q., Ng H.H., Ruan Y. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006, 124:207-219.
24. Black E.P., Huang E., Dressman H., Rempel R., Laakso N., Asa S.L., Ishida S., West M., Nevins J.R. Distinct gene expression phenotypes of cells lacking Rb and Rb family members. Cancer Res 2003, 63:3716-3723.
25. Liu J.M., Long X.H., Zhang G.M., Zhou Y., Chen X.Y., Huang S.H., Liu Z.L., Zhang Z.H. Let-7g reverses malignant phenotype of osteosarcoma cells by targeting aurora-B. Int J Clin Exp Pathol 2014, 7:4596-4606.
26. Ren B., Cam H., Takahashi Y., Volkert T., Terragni J., Young R.A., Dynlacht B.D. E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev 2002, 16:245-256.
27. Lee M.S., Kim H.S., Yeon J.T., Choi S.W., Chun C.H., Kwak H.B., Oh J. GM-CSF regulates fusion of mononuclear osteoclasts into bone-resorbing osteoclasts by activating the Ras/ERK pathway. J Immunol 2009, 183:3390-3399.
28. Forwood M.R. Inducible cyclo-oxygenase (COX-2) mediates the induction of bone formation by mechanical loading in vivo. J Bone Miner Res 1996, 11:1688-1693.
29. Bialek P., Kern B., Yang X., Schrock M., Sosic D., Hong N., Wu H., Yu K., Ornitz D.M., Olson E.N., Justice M.J., Karsenty G. A twist code determines the onset of osteoblast differentiation. Dev Cell 2004, 6:423-435.
30. Iritani B.M., Eisenman R.N. c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc Natl Acad Sci U S A 1999, 96:13180-13185.
31. Attisano L., Wrana J.L. Signal integration in TGF-β, WNT, and Hippo pathways F1000. In: Prime Rep 2013, 5:17.
32. van Tienen F.H., Laeremans H., van der Kallen C.J., Smeets H.J. Wnt5b stimulates adipogenesis by activating PPARgamma, and inhibiting the beta-catenin dependent Wnt signaling pathway together with Wnt5a. Biochem Biophys Res Commun 2009, 387:207-211.
33. He T.C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., Morin P.J., Vogelstein B., Kinzler K.W. Identification of c-MYC as a target of the APC pathway. Science 1998, 281:1509-1512.
34. Sherr C.J. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001, 2:731-737.
35. Maestro R., Dei Tos A.P., Hamamori Y., Krasnokutsky S., Sartorelli V., Kedes L., Doglioni C., Beach D.H., Hannon G.J. Twist is a potential oncogene that inhibits apoptosis. Genes Dev 1999, 13:2207-2217.
36. Jacobs J.J., Keblusek P., Robanus-Maandag E., Kristel P., Lingbeek M., Nederlof P.M., van Welsem T., van de Vijver M.J., Koh E.Y., Daley G.Q., van Lohuizen M. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat Genet 2000, 26:291-299.
37. Lingbeek M.E., Jacobs J.J., van Lohuizen M. The T-box repressors TBX2 and TBX3 specifically regulate the tumor suppressor gene p14ARF via a variant T-site in the initiator. J Biol Chem 2002, 277:26120-26127.
38. Sreeramaneni R., Chaudhry A., McMahon M., Sherr C.J., Inoue K. Ras-Raf-Arf signaling critically depends on the Dmp1 transcription factor. Mol Cell Biol 2005, 25:220-232.
39. Cha Y.H., Kim N.H., Park C., Lee I., Kim H.S., Yook J.I. MiRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling. Cell Cycle 2012, 11:1273-1281.
40. Kim N.H., Kim H.S., Kim N.G., Lee I., Choi H.S., Li X.Y., Kang S.E., Cha S.Y., Ryu J.K., Na J.M., Park C., Kim K., Lee S., Gumbiner B.M., Yook J.I., Weiss S.J. p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signal 2011, 4. ra71.
41. Wang J., Shou J., Chen X. Dickkopf-1, an inhibitor of the Wnt signaling pathway, is induced by p53. Oncogene 2000, 19:1843-1848.
42. Lengner C.J., Steinman H.A., Gagnon J., Smith T.W., Henderson J.E., Kream B.E., Stein G.S., Lian J.B., Jones S.N. Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J Cell Biol 2006, 172:909-921.
43. Berman S.D., Yuan T.L., Miller E.S., Lee E.Y., Caron A., Lees J.A. The retinoblastoma protein tumor suppressor is important for appropriate osteoblast differentiation and bone development. Mol Cancer Res 2008, 6:1440-1451.
44. Shimizu T., Ishikawa T., Sugihara E., Kuninaka S., Miyamoto T., Mabuchi Y., Matsuzaki Y., Tsunoda T., Miya F., Morioka H., Nakayama R., Kobayashi E., Toyama Y., Kawai A., Ichikawa H., Hasegawa T., Okada S., Ito T., Ikeda Y., Suda T. Saya H. c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis. Oncogene 2010, 29:5687-5699.
45. Tu X., Delgado-Calle J., Condon K.W., Maycas M., Zhang H., Carlesso N., Taketo M.M., Burr D.B., Plotkin L.I., Bellido T. Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone. Proc Natl Acad Sci U S A 2015, 112:E478-E486.
46. Hens J.R., Wilson K.M., Dann P., Chen X., Horowitz M.C., Wysolmerski J.J. TOPGAL mice show that the canonical Wnt signaling pathway is active during bone development and growth and is activated by mechanical loading in vitro. J Bone Miner Res 2005, 20:1103-1113.
47. Asada N., Katayama Y. Regulation of hematopoiesis in endosteal microenvironments. Int J Hematol 2014, 99:679-684.
48. Kamioka H., Honjo T., Takano-Yamamoto T. A three-dimensional distribution of osteocyte processes revealed by the combination of confocal laser scanning microscopy and differential interference contrast microscopy. Bone 2001, 28:145-149.
49. Wang K., Keightley A., Veno P., Dusevich V., Tiede-Lewis L., Bonewald L., Dallas S.L. Osteocyte microvesicles in cell-cell communication in bone. J Bone Miner Res 2014, 29(Suppl 1). (http://www.asbmr.org/education/2014-abstracts. Accessed October 16, 2014).
50. Qing H., Ardeshirpour L., Pajevic P.D., Dusevich V., Jahn K., Kato S., Wysolmerski J., Bonewald L.F. Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation. J Bone Miner Res 2012, 27:1018-1029.
51. Sakai A., Sakata T., Tanaka S., Okazaki R., Kunugita N., Norimura T., Nakamura T. Disruption of the p53 gene results in preserved trabecular bone mass and bone formation after mechanical unloading. J Bone Miner Res 2002, 17:119-127.
52. Robling A.G., Niziolek P.J., Baldridge L.A., Condon K.W., Allen M.R., Alam I., Mantila S.M., Gluhak-Heinrich J., Bellido T.M., Harris S.E., Turner C.H. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 2008, 283:5866-5875.
53. Frost H.M. Bone "mass" and the "mechanostat": a proposal. Anat Rec 1987, 219:1-9.
54. Glass D.A., Bialek P., Ahn J.D., Starbuck M., Patel M.S., Clevers H., Taketo M.M., Long F., McMahon A.P., Lang R.A., Karsenty G. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005, 8:751-764.
55. Cecchini M.G., Hofstetter W., Halasy J., Wetterwald A., Felix R. Role of CSF-1 in bone and bone marrow development. Mol Reprod Dev 1997, 46:75-83. discussion 83-84.
56. Wang X., Kua H.Y., Hu Y., Guo K., Zeng Q., Wu Q., Ng H.H., Karsenty G., de Crombrugghe B., Yeh J., Li B. p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. J Cell Biol 2006, 172:115-125.
57. Fujikawa Y., Sabokbar A., Neale S.D., Itonaga I., Torisu T., Athanasou N.A. The effect of macrophage-colony stimulating factor and other humoral factors (interleukin-1, -3, -6, and -11, tumor necrosis factor-alpha, and granulocyte macrophage-colony stimulating factor) on human osteoclast formation from circulating cells. Bone 2001, 28:261-267.